Thais Federici

Trophic activity of Rabies G protein-pseudotyped equine infectious anemia viral vector mediated IGF-I motor neuron gene transfer in vitro.

A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting.

Gene-based treatment of motor neuron diseases.

X-Linked inhibitor of apoptosis protein gene-based neuroprotection for the peripheral nervous system.

Neuronal affinity of a C7C loop peptide identified through phage display.

Viral clostridial light chain gene-based control of penicillin-induced neocortical seizures.

Ribonucleic acid interference for neurological disorders: candidate diseases, potential targets, and current approaches.

A means for targeting therapeutics to peripheral nervous system neurons with axonal damage.

Reversible unilateral nigrostriatal pathway inhibition induced through expression of adenovirus-mediated clostridial light chain gene in the substantia nigra.

Gene therapy for peripheral nervous system diseases.

Targeted spinal cord therapeutics delivery: stabilized platform and microelectrode recording guidance validation.

Ribonucleic acid interference: the relevance of molecular targeting and therapeutics to neurosurgical practice.

Fusion of the tetanus toxin C fragment binding domain and Bcl-xL for protection of peripheral nerve neurons.

Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS.

Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer.

Optogenetic neuromodulation.

A conditioning lesion provides selective protection in a rat model of Amyotrophic Lateral Sclerosis.

Cervical spinal cord therapeutics delivery: preclinical safety validation of a stabilized microinjection platform.

Invited review: festschrift edition of neurosurgery peripheral nervous system as a conduit for delivering therapies for diabetic neuropathy, amyotrophic lateral sclerosis, and nerve regeneration.

Viral vector-mediated gene transfer for CNS disease.

Preclinical safety validation of a stabilized viral vector direct injection approach to the cervical spinal cord.

Cervical multilevel intraspinal stem cell therapy: assessment of surgical risks in Gottingen minipigs.

Stem cell technology for the study and treatment of motor neuron diseases.

Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery.

Platform and cannula design improvements for spinal cord therapeutics delivery.

Surgical approach and safety of spinal cord stem cell transplantation.

Pain in amyotrophic lateral sclerosis: a neglected aspect of disease.

Assessment of hippocampal adeno-associated viral vector gene delivery via frameless stereotaxis in a nonhuman primate.

Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats.

Gene therapy for amyotrophic lateral sclerosis.

Translational stem cell therapy for amyotrophic lateral sclerosis.

Characterization of a murine model of SMA.

Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients.

Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes.